Asia Pacific Pregnancy Ovulation Testing Market Analysis

In-depth Analysis of Asia Pacific Pregnancy Ovulation Testing Market Industry Landscape

In contemporary times, there's a growing apprehension about the declining birth rates observed in both developed and developing regions. While developing countries like India, China, among others previously experienced higher fertility rates due to lifestyle changes, increased obesity, and significant advancements in healthcare, these rates have plummeted. Environmental factors linked to urbanization and urban lifestyles are also influencing fertility rates, contributing to the escalating instances of male and female infertility. Additionally, the surge in educational attainment among women and their higher employment rates in developing regions are delaying family planning, consequently impacting fertility rates. For instance, statistics from the World Bank reveal a decline in India's fertility rate from 3.311 in 2000 to 2.326 in 2016, while China witnessed a decrease from 2.35 in 1990 to 1.624 in 2016. This downward trend in fertility rates has intensified concerns regarding infertility, thereby stimulating the demand for rapid and self-contained pregnancy and ovulation tests. According to a report by the Asian Development Bank in 2017, over 40.9% of adults in the Asia Pacific region are overweight, compared to 34.6% in 1990.

Advanced technology equipped with high accuracy has emerged in the domain of ovulation and pregnancy tests to optimize the chances of conception. Ovulation tests detect a surge in the luteinizing hormone that precedes ovulation by a day or two, thereby maximizing the chances of conceiving. Pregnancy tests, on the other hand, help identify pregnancy symptoms by detecting human Chorionic Gonadotropin (hCG) produced in the initial days of pregnancy. These tests have gained widespread acceptance, leading to the introduction of numerous products by key market players. For instance, in January 2016, Church & Dwight Co. introduced the FIRST RESPONSE Pregnancy PRO Digital Test & App Access, emphasizing enhanced accuracy. The integration of advanced technology provides consumers with a more convenient and straightforward method to ascertain fertility. In October 2017, SPD Swiss Precision Diagnostics GmbH, a joint venture of Procter & Gamble (P&G) and Alere (now part of the Abbott group), launched the Clearblue Connected Ovulation Test System, the first and sole ovulation test system capable of tracking two distinct hormones with smartphone connectivity. Accurately identifying the precise ovulation time is crucial for women planning conception or contraception. Hence, these technological strides aid in achieving accurate results, thereby expectedly propelling market growth during the forecast period.